Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497. miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer.
|
21350001 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, we found that compound 9d suppressed the proliferation of breast cancer cell lines and induced cellular apoptosis via a mitochondrial pathway with only partial dependence on Raf1 and ERK.
|
27839788 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis.
|
9242379 |
1997 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings support the development of CDK and Raf co-targeting strategies in EGFR/HER-2-overexpressing or RAS/RAF mutant BCs.
|
23908594 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
|
16465392 |
2006 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transfection of the c-raf-1-specific ODN (ODN-Raf) in a breast cancer cell line reduced the protein levels of C-Raf, ErbB2, and their downstream effector cyclin D1 similar to miR-125b.
|
19825990 |
2009 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Despite the low prevalence of activating point mutation of RAS or RAF genes, the RAS-extracellular signal-regulated kinase (ERK) pathway is implicated in breast cancer pathogenesis.
|
25202123 |
2014 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
From these, we validated and further characterized novel gene fusions involving ROS1 tyrosine kinase in angiosarcoma (CEP85L/ROS1), SLC1A2 glutamate transporter in colon cancer (APIP/SLC1A2), RAF1 kinase in pancreatic cancer (ATG7/RAF1) and anaplastic astrocytoma (BCL6/RAF1), EWSR1 in melanoma (EWSR1/CREM), CDK6 kinase in T-cell acute lymphoblastic leukemia (FAM133B/CDK6), and CLTC in breast cancer (CLTC/VMP1).
|
23637631 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that the clinical effectiveness of paclitaxel could be substantially improved by the use of Raf-1 kinase inhibitors, provided that a similar relationship between Raf-1 kinase activity and paclitaxel cytotoxicity exists in the clinic, especially in those tumor sites where paclitaxel is the current treatment of choice e.g., ovarian and breast cancer.
|
9607567 |
1998 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The data from the current study demonstrated that expression of miR-195 was inversely associated with Raf-1 expression in breast cancer cell lines and tissue specimens, and that Raf-1 is the target gene of miR-195.
|
23760062 |
2013 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
There was also a positive correlation between the high level of P-Raf-1 (Ser338) and Pin1 in human tamoxifen-resistant breast cancer and tamoxifen-resistant MCF7 (TAMR-MCF7) cells.
|
22158035 |
2012 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also identified Raf1, which activates the MAPK/ERK signaling pathway, as a target of miR-7-5p and determined that circ_0006528 promotes breast cancer growth, invasion, and migration by promoting the expression of Raf1 and activates the MAPK/ERK pathway.
|
30520151 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Raf-1 kinase inhibitor protein (RKIP) expression was associated with the onset, development, invasion, and metastasis of numerous tumor types including prostate cancer, melanoma, colorectal cancer, liver cancer, and breast cancer.
|
24420151 |
2014 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To investigate the role of Raf-1 kinase expression and its activation in breast cancer, we studied three human breast cancer cell lines expressing varying amounts of EGF receptor to determine the level of Raf-1 protein and the proportion expressed in the higher molecular weight form.
|
7834453 |
1995 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among survivors who received 10 or higher gray breast radiation exposure, a locus on 1q41 was associated with subsequent breast cancer risk (rs4342822, nearest gene PROX1 , risk allele frequency in control subjects [RAF controls ] = 0.46, hazard ratio = 1.92, 95% confidence interval = 1.49 to 2.44, P = 7.09 × 10 -9 ).
|
29059430 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we identified differential Raf1-tr expression in breast cancer cell lines and showed that breast cancer cells with increased Raf1-tr expression become sensitized to bleomycin-induced apoptosis.
|
30106602 |
2019 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.
|
25071141 |
2014 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance.
|
12631622 |
2003 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, we discovered a regulatory role of the circ_0006528-miR-7-5p-Raf1 axis in ADM-resistant breast cancer.
|
28803498 |
2017 |
Breast Carcinoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line.
|
12432273 |
2003 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have investigated whether the raf-1 kinase, a downstream mediator of both receptor tyrosine kinase and protein kinase C signalling, is activated by estrogen (E2) in an estrogen receptor positive human breast cancer cell line.
|
9879662 |
1998 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, Gal-1 knockdown dramatically improved drug sensitivity of breast cancer by reducing P-glycoprotein (P-gp) expression via inhibiting the Raf-1/AP-1 pathway, providing a novel therapeutic target to overcome MDR in breast cancer.
|
28212576 |
2017 |